Objective: The authors sought to determine whether cannabis use is associated with a change in the risk of incident nonmedical prescription opioid use and opioid use disorder at 3-year follow-up.

Method: The authors used logistic regression models to assess prospective associations between cannabis use at wave 1 (2001–2002) and nonmedical prescription opioid use and prescription opioid use disorder at wave 2 (2004–2005) of the National Epidemiologic Survey on Alcohol and Related Conditions. Corresponding analyses were performed among adults with moderate or more severe pain and with nonmedical opioid use at wave 1. Cannabis and prescription opioid use were measured with a structured interview (the Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV version). Other covariates included age, sex, race/ethnicity, anxiety or mood disorders, family history of drug, alcohol, and behavioral problems, and, in opioid use disorder analyses, nonmedical opioid use.

Results: In logistic regression models, cannabis use at wave 1 was associated with increased incident nonmedical prescription opioid use (odds ratio=5.78, 95% CI=4.23–7.90) and opioid use disorder (odds ratio=7.76, 95% CI=4.95–12.16) at wave 2. These associations remained significant after adjustment for background characteristics (nonmedical opioid use: adjusted odds ratio=2.62, 95% CI=1.86–3.69; opioid use disorder: adjusted odds ratio=2.18, 95% CI=1.14–4.14). Among adults with pain at wave 1, cannabis use was also associated with increased incident nonmedical opioid use (adjusted odds ratio=2.99, 95% CI=1.63–5.47) at wave 2; it was also associated with increased incident prescription opioid use disorder, although the association fell short of significance (adjusted odds ratio=2.14, 95% CI=0.95–4.83). Among adults with nonmedical opioid use at wave 1, cannabis use was also associated with an increase in nonmedical opioid use (adjusted odds ratio=3.13, 95% CI=1.19–8.23).

Conclusions: Cannabis use appears to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorder.
cannabis use was associated with a 64% decline in opioid use (N=118) (12). Cannabis exposure has also been associated with increased analgesia among opioid-treated patients with chronic pain (15), suggesting that cannabis may potentiate antinociceptive effects of opioids, permitting lower and presumably safer opioid dosing to achieve comparable analgesia.

Much remains to be learned about the association between cannabis use and nonmedical prescription opioid use or opioid use disorders. No prospective epidemiological or clinical studies have demonstrated that cannabis use reduces use of opioids. Moreover, epidemiologic research suggests that cannabis may actually increase the risk of other drug use disorders, including opioids. A retrospective Australian twin study reported that early initiation of cannabis use was associated with increased risks of other drug use and abuse/dependence, including opioid use and opioid abuse/dependence (16). Prospective epidemiological research further suggests that cannabis use is a risk factor for other drug use disorders (17). However, prospective epidemiological research has not previously examined the specific association between cannabis use and nonmedial prescription opioid use or opioid use disorder to inform clinical practice and policy.

We sought to address this critical gap in knowledge with prospective data from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC), a large, nationally representative sample. We examined the association between cannabis use and incident nonmedical prescription opioid use and disorder 3 years later, after adjusting for several relevant demographic and clinical covariates. We also evaluated whether cannabis use among adults with nonmedical prescription opioid use was associated with a subsequent decrease in nonmedical opioid use.

**METHOD**

**Sample**
The 2001–2002 NESARC (wave 1), and the 2004–2005 follow-up (wave 2) is a nationally representative sample of the noninstitutionalized adult U.S. population conducted by the U.S. Census Bureau under the direction of the National Institute on Alcoholism and Alcohol Abuse (18, 19). The response rate for wave 1 was 81.0%. Excluding ineligible respondents (e.g., those who were deceased), the wave 2 response rate was 86.7%, resulting in a cumulative response rate of 70.2% (N=34,653). Wave 2 NESARC weights include adjustments for nonresponse, demographic factors, and psychiatric diagnoses to ensure that the wave 2 sample approximated the target population, which was the original sample minus attrition between the two waves (18).

**Assessment**
All diagnoses were made according to DSM-IV criteria, using the Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV version (AUDADIS-IV) for waves 1 and 2 (20). Consistent with previous reports, nonmedical use of a prescription opioid was defined as using a prescription analgesic “without a prescription, in greater amounts, more often, or longer than prescribed, or for a reason other than a doctor said you should use them” during the 12 months preceding the interview. More than 30 symptom items were used by the AUDADIS-IV to define 12-month prescription opioid use disorder according to DSM-IV criteria. The NESARC also collected information for other substance use disorders (nicotine dependence, alcohol use disorder, and drug use disorders, including other prescription drug use disorders). The reliability of the AUDADIS-IV prescription opioid use questions (kappa=0.66) and associated substance use disorder diagnoses (kappa=0.53–0.84) are well documented in several psychometric studies, including in clinical (20) and general population (21) samples. Further concurrent and predictive validity of the prescription opioid use disorder diagnosis has been documented by increased risk of related psychopathology, impairment, and probability of seeking treatment (22).

The frequency of past-year cannabis use was assessed with an 11-level item ranging from no use in the past 12 months to use every day in the past 12 months. Cannabis use was collapsed into a four-level variable including no use in the past last 12 months, occasional use (at least once a year but less than once a month), frequent use (from once a month or more to twice a week), and very frequent use (from three times a week to every day) (23). A similar four-level scale was developed for past-year prescription opioid use.

Mood disorders included DSM-IV major depressive disorder, dysthymia, bipolar I disorder, and bipolar II disorder. Anxiety disorders included DSM-IV panic disorder, social anxiety disorder, specific phobia, and generalized anxiety disorder. Test-retest reliabilities for AUDADIS-IV mood, anxiety, and personality disorders in the noninstitutionalized population and clinical settings have been found to be fair to good. The criterion validity of mood and substance use disorders with psychiatrist reappraisal has also been found to be good to excellent (kappa values, 0.64–0.83) (24). Family histories of alcohol use disorder, drug use disorders, depression, and antisocial personality disorder referred to first-degree relatives. The test-retest reliability of AUDADIS family history variables has been shown to be very good to excellent (25).

Pain was assessed using the pain item of the Medical Outcomes Study 12-Item Short Form Health Survey, Version 2 (SF-12) (26), a valid measure that is commonly used in population surveys (27). The pain item uses a 5-point scale (not at all, a little bit, moderately, quite a bit, and extremely) to measure the degree to which pain interferes with daily activities during the past 4 weeks (28). The pain measure was collapsed into two levels depending on whether pain was associated with no or little interference (“no pain”), or with moderate to extreme interference (“pain”) (29).

**Statistical Analysis**
Wave 1 descriptive demographic and clinical characteristics were compared between individuals with and without any cannabis use in the year before the wave 1 interview. Group
differences were evaluated with chi-square or t tests. Un-
adjusted percentages of respondents with wave 2 incident
opioid use disorders were determined by frequency of wave
1 cannabis use.

Separate logistic regression models were fitted with non-
medical opioid use and disorder outcomes at wave 2 predicted
by past-year cannabis use at wave 1. To differentiate between
prevalent and incident opioid outcomes at wave 2, we de-
finite four outcomes: 1) prevalent nonmedical opioid use,
defined as any nonmedical opioid use since the wave 1 in-
terview; 2) incident nonmedical opioid use, defined as any
nonmedical opioid use since wave 1, restricted to respond-
ents with no lifetime nonmedical opioid use at wave 1; 3) pre-
valent prescription opioid use disorder, defined as meeting
opioid use disorder criteria since wave 1; and 4) incident
prescription opioid use disorder, defined as meeting opioid use
disorder criteria since wave 1, restricted to respondents with
no lifetime opioid use disorder at wave 1. Results are presented
as unadjusted odds ratios and adjusted odds ratios controlling
for age, sex, race/ethnicity, family history variables, antisocial
personality disorder, and other substance use disorders and
mood or anxiety disorders at wave 1 (29). Adjusted models of
wave 2 opioid use disorder also controlled for wave 1 past-year
nonmedical opioid use. Regressions were fitted among the
overall population of NESARC wave 1 and 2 respondents and
then repeated, as a sensitivity analysis, among respondents
without wave 1 past-year cannabis use disorders and among
respondents with moderate or more severe pain impairment.

We further examined whether, among respondents with
wave 1 past-year nonmedical opioid use, cannabis use was
associated with an increase or decrease in the level of opioid
use at wave 2. A separate logistic regression was fitted for
respondents with wave 1 opioid use and moderate or more
severe pain. All analyses were performed using SUDAAN to
take into account the complex design features of the NESARC.

RESULTS

Background Characteristics of Adults Who Use Cannabis
At wave 1, individuals with any past-year cannabis use were
younger on average than those without cannabis use, more likely
to be male, and more likely to have past-year opioid use disorder,
cannabis use disorder, other substance use disorders, or any
past-year mood or anxiety disorder. They were also significantly
more likely to have a family history of alcohol use disorders, drug
use disorders, depression, and antisocial personality disorder.
The two groups did not differ significantly with respect to the
proportion who reported moderate or more severe pain during
the month before the wave 1 interview (Table 1).

Prospective Associations Between Cannabis Use and
Nonmedical Prescription Opioid Use
Within the overall survey population, cannabis use at wave 1 was
associated with a significant increase in the odds of prevalent
nonmedical prescription opioid use during the follow-up period
(Table 2). After adjustment for the background demographic
and clinical characteristics, a strong association persisted be-
tween wave 1 cannabis use and wave 2 prevalent nonmedical
opioid use. These associations were also observed among adults
without past-year cannabis use disorder and among adults with
moderate or more severe pain at wave 1. Among individuals
without nonmedical opioid use during the 12 months before the
wave 1 interview, there was a significant association between
cannabis use at wave 1 and incident nonmedical opioid use
during the follow-up period. This association was also observed
among adults without cannabis use disorder at wave 1 and
among adults with moderate or more severe pain at wave 1.

In analyses restricted to individuals with past-year non-
medical opioid use, in unadjusted and adjusted regressions,
wave 1 cannabis use was significantly associated with an in-
crease in the level of opioid use during the year before the wave
2 interview. Cannabis use was also associated with lower odds
of decreasing the level of opioid use. When the sample was
further restricted to adults with wave 1 nonmedical opioid use
and moderate or more severe pain, wave 1 cannabis use was
associated with lower unadjusted odds of decreasing opioid
use, although the other regressions did not yield significant
associations. Among individuals with nonmedical opioid use
at wave 1 who either used or did not use cannabis, however,
decreases in opioid use at wave 2 were markedly more common
than increases in opioid use (Table 3).

Prospective Associations Between Cannabis Use and
Prescription Opioid Use Disorder
In unadjusted analyses, the percentage of adults who de-
vloped a new-onset opioid use disorder during the follow-
up period was lowest for individuals who did not use cannabis in
the year before the wave 1 interview (0.51%), followed by
occasional cannabis users (2.86%), frequent cannabis users
(4.30%), and very frequent cannabis users (4.43%) (Figure 1).

In the overall survey population, cannabis use at wave
1 was associated with a significant increase in the odds of prevalent
and incident prescription opioid use disorder during the follow-
up period (Table 4). After adjustment for the background demog-
ographic and clinical covariates, including wave 1 nonmedical
opioid use, significant associations persisted between wave 1 cannabis use and prevalent as
well as incident nonmedical opioid use disorder at wave 2. A similar association was observed among adults without
past-year cannabis use disorders and prevalent opioid use
disorder, although the association with incident opioid use
disorder fell below the level of statistical significance. Among
adults with moderate or more severe pain at wave 1, cannabis
use was associated with prevalent and incident opioid use
disorders in unadjusted analyses and with prevalent opioid
use disorder in adjusted analyses (Table 4).

DISCUSSION
In a nationally representative sample of adults evaluated at
waves 3 years apart, cannabis use was strongly associated
with subsequent onset of nonmedical prescription opioid use

ajp in Advance

ajp.psychiatryonline.org
and opioid use disorder. These results remained robust after controlling for the potentially confounding effects of several demographic and clinical covariates that were strongly associated with cannabis use. The association of cannabis use with the development of nonmedical opioid use was evident among adults without cannabis use disorders and among adults with moderate or more severe pain. Among adults with nonmedical prescription opioid use, cannabis use was associated with an increase in the level of nonmedical prescription opioid use at follow-up.

An independent prospective association between cannabis use and onset of prescription opioid use disorder extends

### TABLE 1. Background Characteristics of NESARC Respondents, by Any Past-Year Cannabis Use at Wave 1a

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cannabis Use (N=1,267)</th>
<th>No Cannabis Use (N=33,352)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>29.91 (10.66)</td>
<td>45.72 (17.27)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>766 (66.49)</td>
<td>13,780 (47.14)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female</td>
<td>501 (33.51)</td>
<td>19,572 (52.86)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td>0.96</td>
</tr>
<tr>
<td>White, non-Hispanic</td>
<td>789 (70.82)</td>
<td>19,360 (70.91)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>478 (29.18)</td>
<td>13,992 (29.09)</td>
<td></td>
</tr>
<tr>
<td>Family history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol use disorders</td>
<td>598 (46.51)</td>
<td>11,636 (33.96)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Drug use disorders</td>
<td>427 (33.08)</td>
<td>5,537 (15.97)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Depression</td>
<td>614 (48.39)</td>
<td>10,503 (31.98)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Antisocial personality disorder</td>
<td>248 (21.42)</td>
<td>902 (2.89)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Painb</td>
<td>254 (20.06)</td>
<td>6,680 (18.60)</td>
<td>0.29</td>
</tr>
<tr>
<td>Nonmedical prescription opioid use,</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>past 12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>1,064 (81.92)</td>
<td>33,020 (98.94)</td>
<td></td>
</tr>
<tr>
<td>Occasional use</td>
<td>108 (10.11)</td>
<td>150 (0.54)</td>
<td></td>
</tr>
<tr>
<td>Frequent use</td>
<td>56 (4.37)</td>
<td>99 (0.32)</td>
<td></td>
</tr>
<tr>
<td>Very frequent use</td>
<td>39 (3.61)</td>
<td>83 (0.21)</td>
<td></td>
</tr>
<tr>
<td>Mental disorders, past 12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opioid use disorder</td>
<td>45 (4.05)</td>
<td>58 (0.18)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cannabis use disorder</td>
<td>443 (36.21)</td>
<td>0 (0.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Other substance use disorder</td>
<td>591 (48.89)</td>
<td>2,160 (6.78)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mood or anxiety disorder</td>
<td>440 (33.00)</td>
<td>5,478 (15.53)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

a NESARC=National Epidemiologic Survey on Alcohol and Related Conditions; wave 1 was conducted in 2001 and 2002. Percentages are based on weighted sampling.

b Pain is defined as presence of pain causing moderate to extreme interference with daily activities in the past 4 weeks.

### TABLE 2. Prospective Associations of Wave 1 Cannabis Use and Wave 2 Prevalent and Incident Nonmedical Prescription Opioid Use in the NESARCa

<table>
<thead>
<tr>
<th>Wave 1 Past-Year Cannabis Use Predicting:</th>
<th>N in Analysis</th>
<th>Odds Ratio</th>
<th>95% CI</th>
<th>Adjusted Odds Ratiob</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall population</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wave 2 prevalent nonmedical opioid use</td>
<td>34,534</td>
<td>8.74</td>
<td>6.98–10.93</td>
<td>3.54</td>
<td>2.74–4.57</td>
</tr>
<tr>
<td>Wave 2 incident nonmedical opioid use</td>
<td>32,888</td>
<td>5.78</td>
<td>4.23–7.90</td>
<td>2.62</td>
<td>1.86–3.69</td>
</tr>
<tr>
<td>Population without wave 1 cannabis use disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wave 2 prevalent nonmedical opioid use</td>
<td>34,091</td>
<td>7.43</td>
<td>5.59–9.87</td>
<td>3.35</td>
<td>2.48–4.52</td>
</tr>
<tr>
<td>Wave 2 incident nonmedical opioid use</td>
<td>32,616</td>
<td>5.67</td>
<td>3.97–8.09</td>
<td>2.78</td>
<td>1.91–4.04</td>
</tr>
<tr>
<td>Population with painc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wave 2 prevalent nonmedical opioid use</td>
<td>6,920</td>
<td>10.30</td>
<td>6.89–15.39</td>
<td>3.97</td>
<td>2.44–6.46</td>
</tr>
<tr>
<td>Wave 2 incident nonmedical opioid use</td>
<td>6,518</td>
<td>6.47</td>
<td>4.09–11.10</td>
<td>2.99</td>
<td>1.63–5.47</td>
</tr>
</tbody>
</table>

a NESARC=National Epidemiologic Survey on Alcohol and Related Conditions; wave 1 was conducted in 2001 and 2002, and wave 2 in 2004 and 2005.

b Adjusted for age, sex, race/ethnicity, other substance use disorders, any mood or anxiety disorder, and family history of drug use disorder, alcohol use disorder, depression, and antisocial personality disorder at wave 1. The “overall population” and “population without wave 1 cannabis use disorders” analyses were also adjusted for pain at wave 1.

c Pain is defined as presence of pain causing moderate to extreme interference with daily activities in the past 4 weeks.
results from previous epidemiological research concerning a link between cannabis use and other forms of problematic drug use (15–17). Previous work in this area has either been retrospective in design (15) or focused on general associations between cannabis use and substance use disorders (17) or problems (16) rather than specifically nonmedical opioid use or opioid use disorder. Because in the present study the association was observed among adults with less than disorder-level of cannabis use and followed a dose-response pattern, it suggests that some increased risk extends to a relatively large population of adult cannabis users. If cannabis use increases opioid use, it is possible that the recent increase in cannabis use (30) may have worsened the opioid crisis.

Several factors may contribute to a tendency for individuals with cannabis use to develop opioid use disorder or increase the frequency of opioid use among opioid users. Heroin and Δ⁹-tetrahydrocannabinol (Δ⁹-THC) have similar effects on dopamine transmission through the μ₁ opioid receptor (31). As compared with controls, adolescent rats exposed to Δ⁹-THC have been shown to develop enhanced heroin self-administration as adults (32). Also in relation to controls, rats exposed to Δ⁹-THC have been found to have a greater behavioral response to morphine challenge (33). These results are consistent with cross-sensitization between cannabis and opioids. In clinical research, cannabis use can lead to behavioral disinhibition, which can increase the risk of using other substances, including opioids (34). Access to cannabis may also provide increased availability and social exposure to other drugs of abuse through peer affiliations (35), although such environmental influences may be less powerful in recent years with increased prevalence of cannabis use and changing public attitudes.

Ecological studies reporting fewer opioid-related deaths (8, 9) and decreased opioid prescribing following passage of

### TABLE 3. Prospective Associations Between Wave 1 Cannabis Use and Increase or Decrease in Nonmedical Prescription Opioid Use at Wave 2 Among Adults With Wave 1 Nonmedical Prescription Opioid Use in the NESARC

<table>
<thead>
<tr>
<th>Wave 1 Past-Year Cannabis Use Predicting:</th>
<th>Respondents With Change in Opioid Use Between Wave 1 and Wave 2</th>
<th>Cannabis Use</th>
<th>No Cannabis Use</th>
<th>Odds Ratio</th>
<th>95% CI</th>
<th>Adjusted Odds Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults with wave 1 nonmedical opioid use</td>
<td>Increase in opioid use at wave 2</td>
<td>9</td>
<td>5.15</td>
<td>4</td>
<td>0.97</td>
<td>5.57</td>
<td>1.47–21.11</td>
</tr>
<tr>
<td></td>
<td>Decrease in opioid use at wave 2</td>
<td>169</td>
<td>81.27</td>
<td>307</td>
<td>93.70</td>
<td>0.29</td>
<td>0.14–0.61</td>
</tr>
<tr>
<td>Adults with wave 1 nonmedical opioid use and pain</td>
<td>Increase in opioid use at wave 2</td>
<td>2</td>
<td>7.78</td>
<td>3</td>
<td>1.97</td>
<td>4.20</td>
<td>0.64–27.50</td>
</tr>
<tr>
<td></td>
<td>Decrease in opioid use at wave 2</td>
<td>53</td>
<td>79.97</td>
<td>96</td>
<td>93.04</td>
<td>0.30</td>
<td>0.10–0.86</td>
</tr>
</tbody>
</table>

a NESARC=National Epidemiologic Survey on Alcohol and Related Conditions; wave 1 was conducted in 2001 and 2002, and wave 2 in 2004 and 2005. Percentages are based on weighted sampling.
b Adjusted for age, sex, race/ethnicity, other substance use disorders, any mood or anxiety disorder, and family history of drug use disorder, alcohol use disorder, depression, and antisocial personality disorder at wave 1.
c Pain is defined as presence of pain causing moderate to extreme interference with daily activities in the past 4 weeks.

### FIGURE 1. Level of Wave 1 Cannabis Use and Incident Wave 2 Prescription Opioid Use Disorder in the NESARC

![Graph showing the level of Wave 1 cannabis use and incident Wave 2 prescription opioid use disorder in NESARC](http://example.com/figure1.jpg)

a NESARC=National Epidemiological Survey on Alcohol and Related Conditions; wave 1 was conducted in 2001 and 2002, and wave 2 in 2004 and 2005.
Overall population

Population without wave 1 cannabis use disorders

Population with pain

Medical marijuana laws (10) have been interpreted in the media (6) and scientific literature (7) as supporting cannabis as a means of reducing opioid use disorder. Yet drawing inferences about the behavior of individuals from aggregated data can be misleading. It is possible, for example, that passage of medical marijuana laws increased local clinical awareness of opioid misuse, leading to earlier detection of high-risk patients or more cautious opioid prescribing practices. At the individual level, cannabis use appears to substantially increase the risk of nonmedical opioid use. Moreover, the general association between cannabis use and subsequent use of illicit drugs is not explained by the legal status of cannabis. An association of early cannabis use with increased subsequent risk of other drug abuse has been reported in prospective co-twin studies in Australia (15), which has restrictive cannabis laws, and in the Netherlands, where cannabis is readily available (36).

In accord with previous studies, several demographic and clinical covariates were associated with cannabis use (17). These findings converge to highlight the wide range of factors that may influence initiation of cannabis. However, because cannabis use was not associated with significant pain at baseline, relief from pain does not appear to be a strong determinant of cannabis use in the general U.S. adult population, although we have no means of evaluating the analgesic effects of cannabis with NESARC data.

This study has several limitations. First, the NESARC sampled individuals age 18 and older. The relationship between cannabis and opioid use may differ in younger individuals (16). Second, information on cannabis and opioid use was based on self-report and was not confirmed with urine toxicology, which may have led to underestimates. Third, the analysis was limited to two time points 3 years apart, which may have been too short an interval to observe delayed consequences of cannabis use on later risk of opioid use. Fourth, the data were collected over a decade ago, and the social context of cannabis use may have changed during this period (30). Nevertheless, the NESARC remains the most recent nationally representative prospective cohort of U.S. adults with detailed information on substance use. Fifth, we were unable to distinguish recreational from medical marijuana use. However, typical medical marijuana participants have been reported to be young males with a history of recreational cannabis use (37), and adults often combine medical and nonmedical cannabis use (38). Sixth, some of the associations are based on a small number of individuals and should therefore be interpreted with appropriate caution. Seventh, the NESARC did not assess inmate populations, which may have a high prevalence of substance use disorders (39). Finally, the assessment of nonmedical use of prescription opioids, although extensive, was not exhaustive and included two nonopioid medications (celecoxib and rofecoxib).

A long-standing controversy in drug research and policy concerns the extent to which use of cannabis predisposes to subsequent use of opioids and other drugs of abuse. We report that cannabis use, even among adults with moderate to severe pain, was associated with a substantially increased risk of nonmedical prescription opioid use at 3-year follow-up. Although the great majority of adults who used cannabis did not go on to initiate or increase their nonmedical opioid use, a strong prospective association between cannabis and opioid use disorder should nevertheless sound a note of caution in ongoing policy discussions concerning cannabis and in clinical debate over authorization of medical marijuana to reduce nonmedical use of prescription opioids and fatal opioid overdoses.

**AUTHOR AND ARTICLE INFORMATION**

From the Department of Psychiatry, New York State Psychiatric Institute and Columbia University Medical Center, New York; and the Division of Epidemiology, Services and Prevention Research, NIDA, Bethesda, Md. Address correspondence to Dr. Olfson (mo49@columbia.edu). Supported by NIH grant DA019606 (to Dr. Olfson). The National Epidemiologic Survey on Alcohol and Related Conditions was sponsored by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and funded in part by the NIAAA Intramural Research Program.
REFERENCES


3. Center for Behavioral Health Statistics and Quality: Key Substance Use and Mental Health Indicators in the United States: Results From the 2015 National Survey on Drug Use and Health (HHS Publication No SMA 16–4984, NSDUH Series H–51). Rockville, Md, Substance Abuse and Mental Health Services Administration, 2016


